Pigeon (7956) Report Interpretation

Overview

This earnings review assesses Pigeon's progress under its FY2026-28 medium-term plan. JPMorgan sees improving overseas execution and raises earnings forecasts and its target price, but concludes that China demand uncertainty and a premium valuation warrant a Neutral rating.

Core views

JPMorgan argues that Pigeon is making tangible progress on the growth strategy in its ninth medium-term plan, which aims to offset lower birthrates in China by expanding nursing-bottle and related baby-product sales overseas. In 2Q FY2026, Pigeon-brand nursing-bottle sales in North America increased about 150% year on year, while Lansinoh-brand nursing-bottle sales in Europe and the US rose about 90%. Across the Americas and Europe, sales grew 23% year on year, accelerating from 9% in 1Q; estimated nursing-bottle sales increased 74%, nipple-cream sales rose 21%, and operating profit improved by ¥500m year on year to ¥500m. JPMorgan attributes the improvement partly to more efficient sales-promotion spending at Lansinoh, although breast-pump sales were estimated to have fallen 6% and several North American channels declined. The 2Q result supported higher forecasts. Consolidated sales were ¥31.3bn, up 10% year on year, while operating profit rose ¥700m to ¥4.2bn, ¥400m above JPMorgan's ¥3.8bn estimate. The institution forecasts FY2026, FY2027 and FY2028 operating profit of ¥15.0bn, ¥16.5bn and ¥17.8bn, respectively—up ¥500m, ¥900m and ¥1.2bn from prior estimates. The FY2026 revision reflects cost-efficiency improvements at Lansinoh and a better sales mix in Japan; higher US nursing-bottle assumptions drive the upward sales and profit revisions from FY2027 onward. Forecast revenue is ¥120.2bn in FY2026, ¥125.1bn in FY2027 and ¥128.8bn in FY2028, while EBIT margin is projected to rise from 12.5% to 13.2% and 13.8% across those years. China remains the principal constraint on the investment case. China-business sales rose 10% in yen terms in 2Q, but JPMorgan estimates mainland-China sales fell 10% in local currency, following 2% growth in 1Q. Currency effects contributed about ¥1.5bn-¥1.6bn to China sales, and the institution believes most of the ¥300m year-on-year increase in China operating profit came from yen weakness. Inventory adjustments at some platforms and promotion costs weighed on results. Pigeon's nursing-bottle share on major Chinese online platforms nevertheless reached almost 50%, from about 49% in 1Q, and estimated bottle sell-out growth improved to 1.4% from 0.8%. JPMorgan expects platform sales momentum to improve from 3Q as inventory adjustments end, but sees uncertainty because the nursing-products market is slowing with falling birthrates. The price target is raised from ¥1,900 to ¥2,150 and the target date moved from December 2026 to December 2027. JPMorgan bases the new target on its FY2027 EPS estimate before goodwill amortization and a 24x target P/E. It derives a theoretical P/E by linking historical P/E to ROE and P/B, then applies an approximately 10% discount for weaker Asian baby-products growth potential caused by lower birthrates. The 24x target multiple is slightly above the 19-22x 12-month-forward consensus P/E range for global toiletries companies, which JPMorgan considers supportable given sales-growth initiatives and dividend yield. However, Pigeon's P/E already exceeded 23x as of 14 August on FY2027 Bloomberg consensus, so the institution believes upside will remain limited until sales expansion translates into a clearer acceleration in profit growth.

Analysis framework

JPMorgan reviews 2Q results by region and product category, identifies the drivers of estimate revisions, and evaluates execution against the FY2026-28 plan. It then values Pigeon using FY2027 EPS before goodwill amortization and a target P/E derived from historical P/E, ROE and P/B relationships, with a discount for demographic pressure in Asia.

Methodology notes

• Valuation methodsP/E and PEG Valuation

  Target P/E valuation based on FY2027 EPS before goodwill amortization

  JPMorgan applies a 24x target P/E to its FY2027 EPS estimate to derive the December 2027 ¥2,150 price target. It benchmarks the result against global toiletries valuations and discounts for slower Asian baby-products growth potential.

• Corporate Fundamentals and FinanceROIC–WACC spread

  ROE and P/B-derived theoretical P/E

  The report decomposes historical P/E into ROE and P/B, estimates the P/B consistent with its FY2027 ROE forecast, and derives a theoretical P/E. This links the valuation multiple to expected profitability rather than applying a peer multiple alone.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Pigeon (7956.T)

  Primary covered company; overseas nursing-bottle expansion and Lansinoh efficiency support earnings, while China-market growth and valuation constrain upside.

  Strengths

  Rapid bottle-sales growth in the Americas and Europe, nearly 50% nursing-bottle share in China, and improving sales-promotion efficiency at Lansinoh.

  Weaknesses

  Local-currency sales declined in mainland China and overseas expansion may take time to make a substantial profit contribution.

  Comparison

  Its target 24x P/E is slightly above the global toiletries 19-22x forward P/E range cited by JPMorgan.

  Risks

  China competition, geopolitical trade disruption, faster demographic decline, product issues, and US health-insurance-related channel changes.

Key data

• 2Q FY2026 sales¥31.3bnUp 10% year on year.
• 2Q FY2026 operating profit¥4.2bnUp ¥700m year on year and ¥400m above JPMorgan's estimate.
• Americas and Europe 2Q sales growth23% YoYAccelerated from 9% in 1Q; estimated nursing-bottle sales rose 74%.
• Mainland China 2Q sales growth-10% YoYJPMorgan estimate on a local-currency basis; China-business sales were up 10% in yen terms.
• FY2026/FY2027/FY2028 operating-profit forecasts¥15.0bn / ¥16.5bn / ¥17.8bnRaised by ¥500m, ¥900m and ¥1.2bn versus prior estimates.
• Target P/E24xUsed with FY2027 EPS before goodwill amortization; roughly 10% discounted for slower Asian baby-products growth potential.

Impact & implications

The report sees overseas bottle-sales expansion and better Lansinoh promotion efficiency as supporting higher earnings, while China remains the key uncertainty. The revised target price reflects improved forecasts, but JPMorgan believes the existing valuation already captures much of the progress until profit growth visibly accelerates.

Risks

• Excessive competition could re-emerge in China's baby-products market.
• Geopolitical risks could disrupt import and export networks.
• Birthrates could fall faster than expected and population aging could accelerate in Asia.
• Consumer-product issues or delayed responses could harm the business.
• Changes to the US health-insurance system could alter distribution channels.

What to watch

• Any recovery in Asian, particularly Chinese, birthrates or material policy action to raise birthrates.
• The pace of growth in the US, ASEAN region and India.
• Rapid yen depreciation against the Chinese yuan.
• Whether new businesses contribute to profit earlier than expected.
• The end of China platform inventory adjustments and subsequent sales momentum.